These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 33663292)

  • 21. HIV incidence after pre-exposure prophylaxis initiation among women and men at elevated HIV risk: A population-based study in rural Kenya and Uganda.
    Koss CA; Havlir DV; Ayieko J; Kwarisiima D; Kabami J; Chamie G; Atukunda M; Mwinike Y; Mwangwa F; Owaraganise A; Peng J; Olilo W; Snyman K; Awuonda B; Clark TD; Black D; Nugent J; Brown LB; Marquez C; Okochi H; Zhang K; Camlin CS; Jain V; Gandhi M; Cohen CR; Bukusi EA; Charlebois ED; Petersen ML; Kamya MR; Balzer LB
    PLoS Med; 2021 Feb; 18(2):e1003492. PubMed ID: 33561143
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pre-exposure prophylaxis to prevent HIV infection: current status, future opportunities and challenges.
    Krakower DS; Mayer KH
    Drugs; 2015 Feb; 75(3):243-51. PubMed ID: 25673022
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Alignment of adherence and risk for HIV acquisition in a demonstration project of pre-exposure prophylaxis among HIV serodiscordant couples in Kenya and Uganda: a prospective analysis of prevention-effective adherence.
    Haberer JE; Kidoguchi L; Heffron R; Mugo N; Bukusi E; Katabira E; Asiimwe S; Thomas KK; Celum C; Baeten JM
    J Int AIDS Soc; 2017 Jul; 20(1):21842. PubMed ID: 28741331
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Systematic review of HIV treatment adherence research among people who inject drugs in the United States and Canada: evidence to inform pre-exposure prophylaxis (PrEP) adherence interventions.
    Bazzi AR; Drainoni ML; Biancarelli DL; Hartman JJ; Mimiaga MJ; Mayer KH; Biello KB
    BMC Public Health; 2019 Jan; 19(1):31. PubMed ID: 30621657
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The promise of pre-exposure prophylaxis with antiretroviral drugs to prevent HIV transmission: a review.
    Hankins CA; Dybul MR
    Curr Opin HIV AIDS; 2013 Jan; 8(1):50-8. PubMed ID: 23201856
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Skating on thin ice: stimulant use and sub-optimal adherence to HIV pre-exposure prophylaxis.
    Hojilla JC; Vlahov D; Glidden DV; Amico KR; Mehrotra M; Hance R; Grant RM; Carrico AW
    J Int AIDS Soc; 2018 Mar; 21(3):e25103. PubMed ID: 29577616
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Review of Real-World Implementation Data on Emtricitabine-Tenofovir Disoproxil Fumarate as HIV Pre-exposure Prophylaxis in the United States.
    Adams JL; Shelley K; Nicol MR
    Pharmacotherapy; 2019 Apr; 39(4):486-500. PubMed ID: 30815960
    [TBL] [Abstract][Full Text] [Related]  

  • 28. HIV pre-exposure prophylaxis for adolescent girls and young women in Africa: from efficacy trials to delivery.
    Celum CL; Delany-Moretlwe S; Baeten JM; van der Straten A; Hosek S; Bukusi EA; McConnell M; Barnabas RV; Bekker LG
    J Int AIDS Soc; 2019 Jul; 22 Suppl 4(Suppl Suppl 4):e25298. PubMed ID: 31328444
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Optimizing Pre-Exposure Antiretroviral Prophylaxis Adherence in Men Who Have Sex with Men: Results of a Pilot Randomized Controlled Trial of "Life-Steps for PrEP".
    Mayer KH; Safren SA; Elsesser SA; Psaros C; Tinsley JP; Marzinke M; Clarke W; Hendrix C; Wade Taylor S; Haberer J; Mimiaga MJ
    AIDS Behav; 2017 May; 21(5):1350-1360. PubMed ID: 27848089
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Seroconversion on preexposure prophylaxis: a case report with segmental hair analysis for timed adherence determination.
    Thaden JT; Gandhi M; Okochi H; Hurt CB; McKellar MS
    AIDS; 2018 Jun; 32(9):F1-F4. PubMed ID: 29683856
    [TBL] [Abstract][Full Text] [Related]  

  • 31. On-demand pre-exposure prophylaxis with tenofovir disoproxil fumarate plus emtricitabine among men who have sex with men with less frequent sexual intercourse: a post-hoc analysis of the ANRS IPERGAY trial.
    Antoni G; Tremblay C; Delaugerre C; Charreau I; Cua E; Rojas Castro D; Raffi F; Chas J; Huleux T; Spire B; Capitant C; Cotte L; Meyer L; Molina JM;
    Lancet HIV; 2020 Feb; 7(2):e113-e120. PubMed ID: 31784343
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Preexposure Prophylaxis for Prevention of HIV Acquisition Among Adolescents: Clinical Considerations, 2020.
    Tanner MR; Miele P; Carter W; Valentine SS; Dunville R; Kapogiannis BG; Smith DK
    MMWR Recomm Rep; 2020 Apr; 69(3):1-12. PubMed ID: 32324724
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Protocol for a multicenter, real-world study of HIV pre-exposure prophylaxis among men who have sex with men in China (CROPrEP).
    Wang H; Zhang Y; Mei Z; Jia Y; Leuba SI; Zhang J; Chu Z; Ding H; Jiang Y; Geng W; Shang H; Xu J
    BMC Infect Dis; 2019 Aug; 19(1):721. PubMed ID: 31416439
    [TBL] [Abstract][Full Text] [Related]  

  • 34. I Can See Clearly Now: Using Active Visualisation to Improve Adherence to ART and PrEP.
    Jones AS; Petrie KJ
    AIDS Behav; 2017 Feb; 21(2):335-340. PubMed ID: 27873082
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Expanded HIV pre-exposure prophylaxis (PrEP) implementation in communities in New South Wales, Australia (EPIC-NSW): design of an open label, single arm implementation trial.
    Zablotska IB; Selvey C; Guy R; Price K; Holden J; Schmidt HM; McNulty A; Smith D; Jin F; Amin J; Cooper DA; Grulich AE;
    BMC Public Health; 2018 Feb; 18(1):210. PubMed ID: 29394918
    [TBL] [Abstract][Full Text] [Related]  

  • 36. HIV pre-exposure prophylaxis in transgender women: a subgroup analysis of the iPrEx trial.
    Deutsch MB; Glidden DV; Sevelius J; Keatley J; McMahan V; Guanira J; Kallas EG; Chariyalertsak S; Grant RM;
    Lancet HIV; 2015 Dec; 2(12):e512-9. PubMed ID: 26614965
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Predicting HIV Pre-exposure Prophylaxis Efficacy for Women using a Preclinical Pharmacokinetic-Pharmacodynamic In Vivo Model.
    Wahl A; Ho PT; Denton PW; Garrett KL; Hudgens MG; Swartz G; O'Neill C; Veronese F; Kashuba AD; Garcia JV
    Sci Rep; 2017 Feb; 7():41098. PubMed ID: 28145472
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Preexposure Prophylaxis For HIV Prevention: What We Know and What We Still Need to Know for Implementation.
    Landovitz RJ
    Top Antivir Med; 2015; 23(2):85-90. PubMed ID: 26200708
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rapid Uptake of Pre-Exposure Prophylaxis After Significant Price Reduction in Germany Highlights Importance of Pre-Exposure Prophylaxis Accessibility.
    Mysior P; Tenberken E; Stecher M; Vehreschild JJ; Schafberger A; Perea I; Brillen AL; Bartmeyer B; Esser S; Bremer V; Marcus U; Hoffmann D; Streeck H
    AIDS Res Hum Retroviruses; 2020 Sep; 36(9):721-733. PubMed ID: 32164425
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Alcohol-antiretroviral interactive toxicity beliefs as a potential barrier to HIV pre-exposure prophylaxis among men who have sex with men.
    Kalichman SC; Eaton L
    J Int AIDS Soc; 2017 Jul; 20(1):21534. PubMed ID: 28715159
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.